Pancreatic Cancer Research

ResearcherOslo University HospitalActive in the last 2 years

Ingvild Farnes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0002-7738-7787; OpenAlex author ID A5075381364. Sources: OpenAlex.

Their work

Papers
8 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
13
Papers, trials and grants by year

2023: 1 paper · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 8

  1. Association between baseline quality of life and survival in patients with non-metastatic, advanced pancreatic cancer. First author DOI 10.1080/00365521.2025.2585113↗
  2. Anatomical Classification and Staging Systems of Borderline Resectable and Locally Advanced Pancreatic Cancer-A Subgroup Analysis of the NORPACT-2 Trial. First author DOI 10.1245/s10434-025-17527-y↗
  3. ASO Author Reflections: From BRPC to LAPC-Rethinking Resectability in Pancreatic Cancer. First author DOI 10.1245/s10434-025-17676-0↗
  4. Surgical, Histopathological, and Quality of Life Outcomes Following Neoadjuvant Chemotherapy and Pancreatectomy for Borderline Resectable and Locally Advanced … Co-author DOI 10.3390/cancers17152505↗
  5. Performance and safety of diagnostic EUS FNA/FNB and therapeutic ERCP in patients with borderline resectable and locally advanced pancreatic cancer - results f… Co-author DOI 10.1080/00365521.2023.2290456↗
  6. Molecular testing for personalized therapy is underutilized in patients with borderline resectable and locally advanced pancreatic cancer - real world data fro… Co-author DOI 10.1080/00365521.2024.2373115↗
  7. Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer. First author DOI 10.3389/fonc.2024.1488749↗
  8. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective coho… Co-author DOI 10.1093/bjsopen/zrad137↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Knut Jørgen Labori · 8 shared papers, 2023–2026 · strength 2.32
  2. Caroline Sophie Verbeke · 5 shared papers, 2023–2025 · strength 1.24
  3. Lars Aabakken · 3 shared papers, 2023–2024 · strength 0.71
  4. Dyre Berg Kleive · 3 shared papers, 2023–2025 · strength 0.70
  5. Pål‐Dag Line · 3 shared papers, 2023–2025 · strength 0.70
  6. Jacob Ghotbi · 2 shared papers, 2025 · strength 0.69
  7. Marianne Jensen Hjermstad · 1 shared paper, 2026 · strength 0.43
  8. Gyda G. Christiansen · 1 shared paper, 2026 · strength 0.43
  9. Peder R. Braadland · 1 shared paper, 2024 · strength 0.23
  10. Sheraz Yaqub · 1 shared paper, 2024 · strength 0.23
  11. Johannes R. Hov · 1 shared paper, 2024 · strength 0.23
  12. Elin Hegland Kure · 1 shared paper, 2024 · strength 0.23
  13. Svein Dueland · 1 shared paper, 2023 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.